Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Simulation and experimental validation of a prototype electron beam linear accelerator for preclinical studies.

Lansonneur P, Favaudon V, Heinrich S, Fouillade C, Verrelle P, De Marzi L.

Phys Med. 2019 Apr;60:50-57. doi: 10.1016/j.ejmp.2019.03.016. Epub 2019 Mar 27.

PMID:
31000086
2.

Experimental Set-up for FLASH Proton Irradiation of Small Animals Using a Clinical System.

Patriarca A, Fouillade C, Auger M, Martin F, Pouzoulet F, Nauraye C, Heinrich S, Favaudon V, Meyroneinc S, Dendale R, Mazal A, Poortmans P, Verrelle P, De Marzi L.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):619-626. doi: 10.1016/j.ijrobp.2018.06.403. Epub 2018 Jul 11.

PMID:
30017793
3.

The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients.

Vozenin MC, De Fornel P, Petersson K, Favaudon V, Jaccard M, Germond JF, Petit B, Burki M, Ferrand G, Patin D, Bouchaab H, Ozsahin M, Bochud F, Bailat C, Devauchelle P, Bourhis J.

Clin Cancer Res. 2019 Jan 1;25(1):35-42. doi: 10.1158/1078-0432.CCR-17-3375. Epub 2018 Jun 6.

4.

Irradiation in a flash: Unique sparing of memory in mice after whole brain irradiation with dose rates above 100Gy/s.

Montay-Gruel P, Petersson K, Jaccard M, Boivin G, Germond JF, Petit B, Doenlen R, Favaudon V, Bochud F, Bailat C, Bourhis J, Vozenin MC.

Radiother Oncol. 2017 Sep;124(3):365-369. doi: 10.1016/j.radonc.2017.05.003. Epub 2017 May 22.

PMID:
28545957
5.

[Hopes of high dose-rate radiotherapy].

Fouillade C, Favaudon V, Vozenin MC, Romeo PH, Bourhis J, Verrelle P, Devauchelle P, Patriarca A, Heinrich S, Mazal A, Dutreix M.

Bull Cancer. 2017 Apr;104(4):380-384. doi: 10.1016/j.bulcan.2017.01.012. Epub 2017 Mar 7. Review. French.

PMID:
28283183
6.

Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.

Huguet F, Fernet M, Giocanti N, Favaudon V, Larsen AK.

Target Oncol. 2016 Jun;11(3):371-81. doi: 10.1007/s11523-015-0403-8.

PMID:
26668065
7.

[Ultrahigh dose-rate, "flash" irradiation minimizes the side-effects of radiotherapy].

Favaudon V, Fouillade C, Vozenin MC.

Cancer Radiother. 2015 Oct;19(6-7):526-31. doi: 10.1016/j.canrad.2015.04.006. Epub 2015 Aug 12. French.

PMID:
26277238
8.

[The radiotherapy FLASH to save healthy tissues].

Favaudon V, Fouillade C, Vozenin MC.

Med Sci (Paris). 2015 Feb;31(2):121-3. doi: 10.1051/medsci/20153102002. Epub 2015 Mar 4. French. No abstract available.

9.

PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levels.

Boudra MT, Bolin C, Chiker S, Fouquin A, Zaremba T, Vaslin L, Biard D, Cordelières FP, Mégnin-Chanet F, Favaudon V, Fernet M, Pennaneach V, Hall J.

Cell Mol Life Sci. 2015 Apr;72(8):1585-97. doi: 10.1007/s00018-014-1765-2. Epub 2014 Oct 22.

PMID:
25336152
10.

Impact of G-quadruplex structures and intronic polymorphisms rs17878362 and rs1642785 on basal and ionizing radiation-induced expression of alternative p53 transcripts.

Perriaud L, Marcel V, Sagne C, Favaudon V, Guédin A, De Rache A, Guetta C, Hamon F, Teulade-Fichou MP, Hainaut P, Mergny JL, Hall J.

Carcinogenesis. 2014 Dec;35(12):2706-15. doi: 10.1093/carcin/bgu206. Epub 2014 Sep 30.

11.

Involvement of the Artemis protein in the relative biological efficiency observed with the 76-MeV proton beam used at the Institut Curie Proton Therapy Center in Orsay.

Calugaru V, Nauraye C, Cordelières FP, Biard D, De Marzi L, Hall J, Favaudon V, Mégnin-Chanet F.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):36-43. doi: 10.1016/j.ijrobp.2014.05.018. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):457.

PMID:
25195988
12.

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.

Guillot C, Favaudon V, Herceg Z, Sagne C, Sauvaigo S, Merle P, Hall J, Chemin I.

BMC Cancer. 2014 Aug 20;14:603. doi: 10.1186/1471-2407-14-603.

13.

Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice.

Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath M, Fouillade C, Poupon MF, Brito I, Hupé P, Bourhis J, Hall J, Fontaine JJ, Vozenin MC.

Sci Transl Med. 2014 Jul 16;6(245):245ra93. doi: 10.1126/scitranslmed.3008973.

14.

Hydrogen bonding to the cysteine ligand of superoxide reductase: acid-base control of the reaction intermediates.

Tremey E, Bonnot F, Moreau Y, Berthomieu C, Desbois A, Favaudon V, Blondin G, Houée-Levin C, Nivière V.

J Biol Inorg Chem. 2013 Oct;18(7):815-30. doi: 10.1007/s00775-013-1025-1. Epub 2013 Aug 6.

PMID:
23917995
15.

Control of the evolution of iron peroxide intermediate in superoxide reductase from Desulfoarculus baarsii. Involvement of lysine 48 in protonation.

Bonnot F, Molle T, Ménage S, Moreau Y, Duval S, Favaudon V, Houée-Levin C, Nivière V.

J Am Chem Soc. 2012 Mar 21;134(11):5120-30. doi: 10.1021/ja209297n. Epub 2012 Mar 7.

16.

The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage.

Sappino AP, Buser R, Seguin Q, Fernet M, Lesne L, Gumy-Pause F, Reith W, Favaudon V, Mandriota SJ.

Oncogenesis. 2012 Apr 16;1:e7. doi: 10.1038/oncsis.2012.7.

17.

The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation.

Bolin C, Boudra MT, Fernet M, Vaslin L, Pennaneach V, Zaremba T, Biard D, Cordelières FP, Favaudon V, Mégnin-Chanet F, Hall J.

Cell Mol Life Sci. 2012 Mar;69(6):951-62. doi: 10.1007/s00018-011-0811-6. Epub 2011 Sep 16.

18.

[New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis].

Huguet F, Fernet M, Monnier L, Touboul E, Favaudon V.

Cancer Radiother. 2011 Aug;15(5):365-75. doi: 10.1016/j.canrad.2011.04.001. Epub 2011 Jun 12. Review. French.

PMID:
21664851
19.

[DNA repair and tumour radiosensitivity: focus on ATM gene].

Hennequin C, Quero L, Favaudon V.

Bull Cancer. 2011 Mar;98(3):239-46. doi: 10.1684/bdc.2011.1324. Review. French.

20.

Radiobiological characterization of two therapeutic proton beams with different initial energy spectra used at the Institut Curie Proton Therapy Center in Orsay.

Calugaru V, Nauraye C, Noël G, Giocanti N, Favaudon V, Mégnin-Chanet F.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1136-43. doi: 10.1016/j.ijrobp.2010.09.003. Epub 2010 Nov 13.

PMID:
21075549
21.

Ataxia telangiectasia mutated (ATM) inhibition transforms human mammary gland epithelial cells.

Mandriota SJ, Buser R, Lesne L, Stouder C, Favaudon V, Maechler P, Béna F, Clément V, Rüegg C, Montesano R, Sappino AP.

J Biol Chem. 2010 Apr 23;285(17):13092-106. doi: 10.1074/jbc.M109.078360. Epub 2010 Feb 22.

22.

Photochemical processes observed during the reaction of superoxide reductase from Desulfoarculus baarsii with superoxide: re-evaluation of the reaction mechanism.

Bonnot F, Houée-Levin C, Favaudon V, Nivière V.

Biochim Biophys Acta. 2010 Apr;1804(4):762-7. doi: 10.1016/j.bbapap.2009.11.019. Epub 2009 Dec 2.

23.

Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity.

Fernet M, Mégnin-Chanet F, Hall J, Favaudon V.

DNA Repair (Amst). 2010 Jan 2;9(1):48-57. doi: 10.1016/j.dnarep.2009.10.006. Epub 2009 Nov 18.

PMID:
19926348
24.

Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.

Quéro L, Giocanti N, Hennequin C, Favaudon V.

Prostate. 2010 Mar 1;70(4):401-11. doi: 10.1002/pros.21074.

PMID:
19902473
25.

[Biological basis of chemo-radiotherapy associations].

Hennequin C, Quero L, Favaudon V.

Bull Cancer. 2009 Mar;96(3):329-36. doi: 10.1684/bdc.2008.0839. Review. French.

26.

PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility.

Godon C, Cordelières FP, Biard D, Giocanti N, Mégnin-Chanet F, Hall J, Favaudon V.

Nucleic Acids Res. 2008 Aug;36(13):4454-64. doi: 10.1093/nar/gkn403. Epub 2008 Jul 4.

27.

Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells.

Seifeddine R, Dreiem A, Blanc E, Fulchignoni-Lataud MC, Le Frère Belda MA, Lecuru F, Mayi TH, Mazure N, Favaudon V, Massaad C, Barouki R, Massaad-Massade L.

Cancer Res. 2008 Apr 1;68(7):2158-65. doi: 10.1158/0008-5472.CAN-07-1190.

28.

Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells.

Huguet F, Giocanti N, Hennequin C, Croisy M, Touboul E, Favaudon V.

Mol Cancer Ther. 2008 Feb;7(2):398-406. doi: 10.1158/1535-7163.MCT-07-2023.

29.

DNA double-strand break repair defects in syndromes associated with acute radiation response: at least two different assays to predict intrinsic radiosensitivity?

Joubert A, Zimmerman KM, Bencokova Z, Gastaldo J, Chavaudra N, Favaudon V, Arlett CF, Foray N.

Int J Radiat Biol. 2008 Feb;84(2):107-25. doi: 10.1080/09553000701797039.

PMID:
18246480
30.

[Determinants and predictive factors of tumour radiosensitivity].

Hennequin C, Quero L, Favaudon V.

Cancer Radiother. 2008 Jan;12(1):3-13. doi: 10.1016/j.canrad.2007.11.007. Epub 2008 Jan 9. Review. French.

PMID:
18187356
31.

Hypoxia and estrogen co-operate to regulate gene expression in T-47D human breast cancer cells.

Seifeddine R, Dreiem A, Tomkiewicz C, Fulchignoni-Lataud MC, Brito I, Danan JL, Favaudon V, Barouki R, Massaad-Massade L.

J Steroid Biochem Mol Biol. 2007 May;104(3-5):169-79. Epub 2007 Mar 24.

PMID:
17475478
32.

Detoxification of superoxide without production of H2O2: antioxidant activity of superoxide reductase complexed with ferrocyanide.

Molina-Heredia FP, Houée-Levin C, Berthomieu C, Touati D, Tremey E, Favaudon V, Adam V, Nivière V.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14750-5. Epub 2006 Sep 25.

33.

Selective radiosensitization by nitric oxide in tumor cell lines.

Policastro L, Duran H, Henry Y, Molinari B, Favaudon V.

Cancer Lett. 2007 Apr 8;248(1):123-30. Epub 2006 Aug 8.

PMID:
16899337
34.
35.

[Targeted therapies and radiotherapy].

Hennequin C, Giocanti N, Favaudon V.

Bull Cancer. 2005 Dec;92(12):1085-92. French.

36.

[Biological basis for concomitant chemoradiotherapy in carcinomas].

Favaudon V, Noël G.

Bull Cancer. 2005 Dec;92(12):1027-31. French.

37.

A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin.

Reis C, Giocanti N, Hennequin C, Mégnin-Chanet F, Fernet M, Filomenko R, Bettaieb A, Solary E, Favaudon V.

Mol Cancer Ther. 2005 Oct;4(10):1457-64.

38.

The repair rate of radiation-induced DNA damage: a stochastic interpretation based on the gamma function.

Foray N, Charvet AM, Duchemin D, Favaudon V, Lavalette D.

J Theor Biol. 2005 Oct 21;236(4):448-58.

PMID:
15975603
39.

Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway.

Deriano L, Guipaud O, Merle-Béral H, Binet JL, Ricoul M, Potocki-Veronese G, Favaudon V, Maciorowski Z, Muller C, Salles B, Sabatier L, Delic J.

Blood. 2005 Jun 15;105(12):4776-83. Epub 2005 Feb 17.

40.

[Targeted drugs in radiation therapy].

Favaudon V, Hennequin C.

Cancer Radiother. 2004 Nov;8 Suppl 1:S114-20. French.

PMID:
15679256
41.

Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro.

Giocanti N, Hennequin C, Rouillard D, Defrance R, Favaudon V.

Br J Cancer. 2004 Dec 13;91(12):2026-33.

42.

Thioredoxin Ch1 of Chlamydomonas reinhardtii displays an unusual resistance toward one-electron oxidation.

Sicard-Roselli C, Lemaire S, Jacquot JP, Favaudon V, Marchand C, Houée-Levin C.

Eur J Biochem. 2004 Sep;271(17):3481-7.

43.

Superoxide reductase from Desulfoarculus baarsii: identification of protonation steps in the enzymatic mechanism.

Nivière V, Asso M, Weill CO, Lombard M, Guigliarelli B, Favaudon V, Houée-Levin C.

Biochemistry. 2004 Jan 27;43(3):808-18.

44.

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery.

Noël G, Giocanti N, Fernet M, Mégnin-Chanet F, Favaudon V.

BMC Cell Biol. 2003 Jul 16;4:7.

45.

[Chemoradiotherapy of solid tumours in the adult: current views and perspectives].

Noël G, Mazeron JJ, Favaudon V.

Bull Cancer. 2003 Jan;90(1):85-92. French.

46.

Constitutive association of BRCA1 and c-Abl and its ATM-dependent disruption after irradiation.

Foray N, Marot D, Randrianarison V, Venezia ND, Picard D, Perricaudet M, Favaudon V, Jeggo P.

Mol Cell Biol. 2002 Jun;22(12):4020-32.

48.

Biological basis for chemo-radiotherapy interactions.

Hennequin C, Favaudon V.

Eur J Cancer. 2002 Jan;38(2):223-30.

PMID:
11803139
49.

Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation.

Fernet M, Ponette V, Deniaud-Alexandre E, Ménissier-De Murcia J, De Murcia G, Giocanti N, Megnin-Chanet F, Favaudon V.

Int J Radiat Biol. 2000 Dec;76(12):1621-9.

PMID:
11133044
50.

[Clinical aspects of research in radiobiology. Past and future directions].

Hennequin C, Favaudon V.

Cancer Radiother. 2000 Sep-Oct;4(5):385-91. Review. French.

PMID:
11098225

Supplemental Content

Loading ...
Support Center